- Home
- CUBI vs NVCR Comparison
CUBI vs NVCR Comparison
Compare CUBI & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBI
- NVCR
- Stock Information
- Founded
- CUBI 1994
- NVCR 2000
- Country
- CUBI United States
- NVCR Jersey
- Employees
- CUBI N/A
- NVCR N/A
- Industry
- CUBI Major Banks
- NVCR Medical/Dental Instruments
- Sector
- CUBI Finance
- NVCR Health Care
- Exchange
- CUBI Nasdaq
- NVCR Nasdaq
- Market Cap
- CUBI 1.4B
- NVCR 1.8B
- IPO Year
- CUBI 2012
- NVCR 2015
- Fundamental
- Price
- CUBI $46.46
- NVCR $17.49
- Analyst Decision
- CUBI Buy
- NVCR Buy
- Analyst Count
- CUBI 8
- NVCR 5
- Target Price
- CUBI $63.86
- NVCR $26.60
- AVG Volume (30 Days)
- CUBI 290.2K
- NVCR 1.3M
- Earning Date
- CUBI 10-31-2024
- NVCR 10-30-2024
- Dividend Yield
- CUBI N/A
- NVCR N/A
- EPS Growth
- CUBI 33.08
- NVCR N/A
- EPS
- CUBI 7.41
- NVCR N/A
- Revenue
- CUBI $722,462,000.00
- NVCR $549,964,000.00
- Revenue This Year
- CUBI N/A
- NVCR $16.23
- Revenue Next Year
- CUBI $11.71
- NVCR $6.09
- P/E Ratio
- CUBI $6.12
- NVCR N/A
- Revenue Growth
- CUBI 25.87
- NVCR 8.33
- 52 Week Low
- CUBI $38.69
- NVCR $10.87
- 52 Week High
- CUBI $68.49
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- CUBI 48.18
- NVCR 43.24
- Support Level
- CUBI $44.31
- NVCR $15.61
- Resistance Level
- CUBI $47.11
- NVCR $17.31
- Average True Range (ATR)
- CUBI 1.57
- NVCR 1.29
- MACD
- CUBI 0.05
- NVCR 0.05
- Stochastic Oscillator
- CUBI 28.96
- NVCR 11.59
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources, and Financial Products and Services. The majority of revenue is derived from commercial lending.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.